Your browser doesn't support javascript.
loading
Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.
Domingo, Enric; Camps, Carme; Kaisaki, Pamela J; Parsons, Marie J; Mouradov, Dmitri; Pentony, Melissa M; Makino, Seiko; Palmieri, Michelle; Ward, Robyn L; Hawkins, Nicholas J; Gibbs, Peter; Askautrud, Hanne; Oukrif, Dahmane; Wang, Haitao; Wood, Joe; Tomlinson, Evie; Bark, Yasmine; Kaur, Kulvinder; Johnstone, Elaine C; Palles, Claire; Church, David N; Novelli, Marco; Danielsen, Havard E; Sherlock, Jon; Kerr, David; Kerr, Rachel; Sieber, Oliver; Taylor, Jenny C; Tomlinson, Ian.
Affiliation
  • Domingo E; Oxford Centre for Cancer Gene Research, Wellcome Trust Centre for Human Genetics, Oxford, UK; Genomic Medicine Theme, National Institute for Health Research Oxford Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, Oxford, UK; Department of Oncology, University of Oxford, Oxford,
  • Camps C; Genomic Medicine Theme, National Institute for Health Research Oxford Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, Oxford, UK.
  • Kaisaki PJ; Genomic Medicine Theme, National Institute for Health Research Oxford Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, Oxford, UK.
  • Parsons MJ; Systems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australia; Department of Surgery, University of Melbourne, Parkville, VIC, Australia.
  • Mouradov D; Systems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia.
  • Pentony MM; Genomic Medicine Theme, National Institute for Health Research Oxford Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, Oxford, UK.
  • Makino S; Oxford Centre for Cancer Gene Research, Wellcome Trust Centre for Human Genetics, Oxford, UK.
  • Palmieri M; Systems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia.
  • Ward RL; Office of the Deputy Vice-Chancellor (Research), University of Queensland, Brisbane, QLD, Australia.
  • Hawkins NJ; Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Gibbs P; Systems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia; Department of Medical Oncology, Royal Melbourne Hospital, Parkville, VIC, Australia.
  • Askautrud H; Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
  • Oukrif D; Department of Histopathology, University College London, London, UK.
  • Wang H; Department of Oncology, University of Oxford, Oxford, UK.
  • Wood J; Thermo Fisher Scientific, Paisley, UK.
  • Tomlinson E; Department of Oncology, University of Oxford, Oxford, UK.
  • Bark Y; Department of Oncology, University of Oxford, Oxford, UK.
  • Kaur K; Genomic Medicine Theme, National Institute for Health Research Oxford Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, Oxford, UK.
  • Johnstone EC; Department of Oncology, University of Oxford, Oxford, UK.
  • Palles C; Oxford Centre for Cancer Gene Research, Wellcome Trust Centre for Human Genetics, Oxford, UK.
  • Church DN; Oxford Centre for Cancer Gene Research, Wellcome Trust Centre for Human Genetics, Oxford, UK; Genomic Medicine Theme, National Institute for Health Research Oxford Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, Oxford, UK.
  • Novelli M; Department of Histopathology, University College London, London, UK.
  • Danielsen HE; Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Nuffield Department of Clinical and Laboratory Science, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford, UK.
  • Sherlock J; Thermo Fisher Scientific, Paisley, UK.
  • Kerr D; Nuffield Department of Clinical and Laboratory Science, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford, UK.
  • Kerr R; Department of Oncology, University of Oxford, Oxford, UK.
  • Sieber O; Systems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australia; Department of Surgery, University of Melbourne, Parkville, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia; School of B
  • Taylor JC; Genomic Medicine Theme, National Institute for Health Research Oxford Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, Oxford, UK.
  • Tomlinson I; Oxford Centre for Cancer Gene Research, Wellcome Trust Centre for Human Genetics, Oxford, UK; Genomic Medicine Theme, National Institute for Health Research Oxford Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, Oxford, UK; Cancer Genetics and Evolution Laboratory, Institute of
Lancet Gastroenterol Hepatol ; 3(9): 635-643, 2018 09.
Article in En | MEDLINE | ID: mdl-30042065
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Colorectal Neoplasms / Biomarkers, Tumor / Mutation Type of study: Clinical_trials / Prognostic_studies Limits: Humans Country/Region as subject: Oceania Language: En Journal: Lancet Gastroenterol Hepatol Year: 2018 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Colorectal Neoplasms / Biomarkers, Tumor / Mutation Type of study: Clinical_trials / Prognostic_studies Limits: Humans Country/Region as subject: Oceania Language: En Journal: Lancet Gastroenterol Hepatol Year: 2018 Type: Article